StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Get Rating) in a research report released on Thursday. The brokerage issued a strong-buy rating on the biopharmaceutical company’s stock.
Vanda Pharmaceuticals Price Performance
NASDAQ:VNDA opened at $6.52 on Thursday. The business’s 50-day moving average is $7.08 and its two-hundred day moving average is $8.76. Vanda Pharmaceuticals has a 12 month low of $6.05 and a 12 month high of $12.34. The firm has a market capitalization of $370.21 million, a PE ratio of 54.34 and a beta of 0.72.
Insider Buying and Selling at Vanda Pharmaceuticals
In other Vanda Pharmaceuticals news, SVP Timothy Williams sold 8,437 shares of the firm’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $6.24, for a total value of $52,646.88. Following the transaction, the senior vice president now directly owns 111,814 shares of the company’s stock, valued at $697,719.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Mihael Hristos Polymeropoulos sold 22,426 shares of Vanda Pharmaceuticals stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $6.23, for a total transaction of $139,713.98. Following the sale, the chief executive officer now directly owns 1,499,440 shares of the company’s stock, valued at $9,341,511.20. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Timothy Williams sold 8,437 shares of Vanda Pharmaceuticals stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $6.24, for a total value of $52,646.88. Following the sale, the senior vice president now directly owns 111,814 shares in the company, valued at $697,719.36. The disclosure for this sale can be found here. Insiders have sold 46,549 shares of company stock valued at $290,324 over the last three months. 7.00% of the stock is owned by company insiders.
Institutional Trading of Vanda Pharmaceuticals
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals, Inc engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.
- Get a free copy of the StockNews.com research report on Vanda Pharmaceuticals (VNDA)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.